Analysts Expect Tyme Technologies Inc (TYME) to Post -$0.08 Earnings Per Share

Wall Street analysts forecast that Tyme Technologies Inc (NASDAQ:TYME) will report earnings per share (EPS) of ($0.08) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Tyme Technologies’ earnings. Tyme Technologies posted earnings of ($0.06) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 33.3%. The firm is scheduled to report its next earnings results on Wednesday, June 12th.

According to Zacks, analysts expect that Tyme Technologies will report full year earnings of ($0.29) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.34) per share. Zacks’ EPS averages are an average based on a survey of research analysts that follow Tyme Technologies.

Tyme Technologies (NASDAQ:TYME) last announced its earnings results on Monday, February 11th. The company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08).

A number of equities analysts have weighed in on TYME shares. HC Wainwright set a $10.00 target price on Tyme Technologies and gave the stock a “buy” rating in a research note on Tuesday, February 26th. BidaskClub lowered Tyme Technologies from a “sell” rating to a “strong sell” rating in a research note on Tuesday, March 5th. Finally, Zacks Investment Research lowered Tyme Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $7.83.

NASDAQ TYME traded down $0.10 during trading on Friday, reaching $1.52. The company’s stock had a trading volume of 545,066 shares, compared to its average volume of 720,740. The firm has a market capitalization of $157.77 million, a P/E ratio of -7.24 and a beta of 0.22. Tyme Technologies has a one year low of $1.51 and a one year high of $4.64.

In other news, Director Douglas A. Michels acquired 20,000 shares of Tyme Technologies stock in a transaction dated Thursday, February 14th. The shares were purchased at an average cost of $3.26 per share, for a total transaction of $65,200.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 53.90% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in TYME. Wells Fargo & Company MN increased its position in shares of Tyme Technologies by 149.1% during the 3rd quarter. Wells Fargo & Company MN now owns 266,026 shares of the company’s stock valued at $739,000 after purchasing an additional 159,251 shares during the last quarter. BlackRock Inc. increased its position in shares of Tyme Technologies by 3.6% during the 3rd quarter. BlackRock Inc. now owns 2,065,741 shares of the company’s stock valued at $5,744,000 after purchasing an additional 71,188 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Tyme Technologies during the 3rd quarter valued at about $100,000. Vanguard Group Inc. increased its position in shares of Tyme Technologies by 60.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,865,160 shares of the company’s stock valued at $5,186,000 after purchasing an additional 699,871 shares during the last quarter. Finally, Vanguard Group Inc increased its position in shares of Tyme Technologies by 60.1% during the 3rd quarter. Vanguard Group Inc now owns 1,865,160 shares of the company’s stock valued at $5,186,000 after purchasing an additional 699,871 shares during the last quarter. Hedge funds and other institutional investors own 16.08% of the company’s stock.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Featured Article: Cost of Equity For A Business, Investors

Get a free copy of the Zacks research report on Tyme Technologies (TYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.